Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-42

As a shareholder who got stopped out recently, I would like to buy back in at some point but have a couple concerns I would like to resolve first. One is the lack of explanation around the burns trial progress and the other is about the recent IV trial results that I don't really understand. The plasma concentrations results seem to show that the kidney is filtering the R327 very efficiently and sending it to the urine. This looks good for the UTI potential, but not so good for other infections (from my non-medical background). I also don't understand how the concentrated R327 in the urine would then make its way back into the bladder / UTI tissue? to treat the infection. Would the R327 keep passing back from the urine to the blood stream / tissue again?